350 results on '"Sattler, Martin"'
Search Results
2. Dual therapeutic targeting of MYC and JUNB transcriptional programs for enhanced anti-myeloma activity
3. Exploring the accessibility of primary health care data in Europe's COVID-19 response: developing key indicators for managing future pandemics (Eurodata study)
4. Spatial iTME analysis of KRAS mutant NSCLC and immunotherapy outcome
5. Correction: Mcl-1 confers protection of Her2-positive breast cancer cells to hypoxia: therapeutic implications
6. Precision oncology provides opportunities for targeting KRAS-inhibitor resistance
7. Phenotypic Switching of Naïve T Cells to Immune-Suppressive Treg-Like Cells by Mutant KRAS.
8. EPHA2 mutations with oncogenic characteristics in squamous cell lung cancer and malignant pleural mesothelioma.
9. Small molecule inhibition of deubiquitinating enzyme JOSD1 as a novel targeted therapy for leukemias with mutant JAK2
10. The Role of Surgery in Pleural Mesothelioma
11. JunB is a key regulator of multiple myeloma bone marrow angiogenesis
12. BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma
13. Essential role of the histone lysine demethylase KDM4A in the biology of malignant pleural mesothelioma (MPM)
14. The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC)
15. Primary care indicators for disease burden, monitoring and surveillance of COVID-19 in 31 European countries: Eurodata Study
16. Synergy between BRD9- and IKZF3-Targeting as a Therapeutic Strategy for Multiple Myeloma
17. Primary care indicators for disease burden, monitoring and surveillance of COVID-19 in 31 European countries: Eurodata Study
18. Current therapies under investigation for COVID-19: potential COVID-19 treatments
19. Inhibition of the deubiquitinase USP10 induces degradation of SYK
20. Evaluation of ERK as a therapeutic target in acute myelogenous leukemia
21. General practitioners’ deprescribing decisions in older adults with polypharmacy: a case vignette study in 31 countries
22. Chimeric Antigen Receptor T Cell Therapy in Acute Myeloid Leukemia: Trials and Tribulations
23. Acquired resistance to KRAS G12C small-molecule inhibitors via genetic/nongenetic mechanisms in lung cancer
24. Patient Characteristics and General Practitioners’ Advice to Stop Statins in Oldest-Old Patients: a Survey Study Across 30 Countries
25. Rationally derived drug combinations with the novel Mcl-1 inhibitor EU-5346 in breast cancer
26. Repurposing of Kinase Inhibitors for Treatment of COVID-19
27. Publisher Correction: JunB is a key regulator of multiple myeloma bone marrow angiogenesis
28. Abstract 6248: Inhibiting β-catenin in AML by targeting DDX5
29. Supplementary Table I from Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097
30. Supplementary Figures 1-7 from Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097
31. Data from Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097
32. Supplementary Figure Legends from Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097
33. Supplementary Figures from Upregulation of IGF1R by Mutant RAS in Leukemia and Potentiation of RAS Signaling Inhibitors by Small-Molecule Inhibition of IGF1R
34. Supplementary Data from Ethnic Differences and Functional Analysis of MET Mutations in Lung Cancer
35. Supplementary Figure Legends from Upregulation of IGF1R by Mutant RAS in Leukemia and Potentiation of RAS Signaling Inhibitors by Small-Molecule Inhibition of IGF1R
36. Data from Upregulation of IGF1R by Mutant RAS in Leukemia and Potentiation of RAS Signaling Inhibitors by Small-Molecule Inhibition of IGF1R
37. Data from Ethnic Differences and Functional Analysis of MET Mutations in Lung Cancer
38. Supplementary Table 2 from Paxillin Is a Target for Somatic Mutations in Lung Cancer: Implications for Cell Growth and Invasion
39. Supplementary Figure 2 from Paxillin Is a Target for Somatic Mutations in Lung Cancer: Implications for Cell Growth and Invasion
40. Supplementary Figure 3 from Paxillin Is a Target for Somatic Mutations in Lung Cancer: Implications for Cell Growth and Invasion
41. Supplementary Figure 4 from Paxillin Is a Target for Somatic Mutations in Lung Cancer: Implications for Cell Growth and Invasion
42. Data from Paxillin Is a Target for Somatic Mutations in Lung Cancer: Implications for Cell Growth and Invasion
43. Supplementary Table 1 from Up-Regulation of c-Jun Inhibits Proliferation and Induces Apoptosis via Caspase-Triggered c-Abl Cleavage in Human Multiple Myeloma
44. Supplementary Figure 1 from Paxillin Is a Target for Somatic Mutations in Lung Cancer: Implications for Cell Growth and Invasion
45. Supplementary Table 4 from Paxillin Is a Target for Somatic Mutations in Lung Cancer: Implications for Cell Growth and Invasion
46. Supplementary Figure 5 from Paxillin Is a Target for Somatic Mutations in Lung Cancer: Implications for Cell Growth and Invasion
47. Supplementary Data 1-4, Table from Targeting Angiogenesis via a c-Myc/Hypoxia-Inducible Factor-1α–Dependent Pathway in Multiple Myeloma
48. Supplementary Legends and Figures 1-2 from Up-Regulation of c-Jun Inhibits Proliferation and Induces Apoptosis via Caspase-Triggered c-Abl Cleavage in Human Multiple Myeloma
49. Supplementary Table 1 from Paxillin Is a Target for Somatic Mutations in Lung Cancer: Implications for Cell Growth and Invasion
50. Supplementary Table 3 from Paxillin Is a Target for Somatic Mutations in Lung Cancer: Implications for Cell Growth and Invasion
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.